RxDoctor Payments Data

Simi Vincent, MD

Infectious Disease · Knoxville, TNNPI 1902836620

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,315 of the $7,118 with a category attached, or 88.7%. 14 manufacturers reported payments, led by Insmed, Inc. at 30.6% of the total.

$7,118in general payments, 2019–2025

Across 363 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insmed, Inc.$2K
  • AbbVie$1K
  • Merck$658
  • Shionogi Inc$538
  • Melinta Therapeutics, LLC$483
  • Astellas Pharma US Inc$463
  • plus $1K from 8 others

What the payments were for

  • Food & beverage$6,31589%
  • Education$77611%
  • Gifts$270%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,118 in reported general payments places this provider in the 85th percentile of 156 infectious disease providers in Tennessee.

See all infectious disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$33,090
Medicare patients
125
Services billed
248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CresembaIsavuconazonium Sulfate11$72,245
Vancomycin Hcl57$9,594
Cefepime Hcl37$6,684
Ampicillin Sodium28$6,546
Itraconazole14$2,484
Rifampin14$2,348
Ethambutol Hcl28$1,451
Doxycycline Hyclate25$1,194
Cephalexin22$1,134
Azithromycin28$977
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav14$547

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncCresemba$463$72,24511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 156 infectious disease providers in Tennessee.

Other infectious disease in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →